Rare diseases
Investigational molecules
Locations
Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors
BelgiumStudy of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients
FranceZongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations
FranceObrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients
AustriaA Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer
AustriaPhase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients
AustriaA study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer
FranceStudy of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases
PolandComparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
AustriaA study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer
CzechiaA study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer
FranceA study of ABBV-706 and atezolizumab for patients with previously untreated extensive stage small cell lung cancer
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
